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1736-61 Economic Impact of Advancing Implantable
Cardloverter Defibrillator Technologies: Decreased
Monetary Costs and Earlier Hospital Discharge
Thomas M. Munger, Marshall S. Stanton, Win K. Shen, Michael J. Osborn, Douglas
L. Packer, Raul E. Espinosa, Douglas L. Wood, Stephen C. Hammill. Mayo
Foundation, Rochester, MN
The recent advances in implantable cardioverter defibrillator (ICO) technolo-
gies allow ICOs with non-thoracotomy leads (NTL), obviating the need for
open chest surgery; smaller generator volumes allow prepectoral implant of
NTL-ICOs, obviating the need for abdominal surgery. To formally assess the
economic impact of these improvements, the physician and hospitalization
charges, (implant to discharge) for 36 patients who received ICO systems
(same manufacturer; 9/92-1/94) were determined. Nine patients received
the ICO epicardial without other cardiac surgery (EPI); 15 received an NTL-
ICO subrectus (NTL AB); 12 received a smaller volume NTL-ICO prepectoral
(NTL PP). [P-values are EPI vs NTL AB / NTL AB vs NTL PP].
EPI NTLAB NTL PP p-value
Age (Vrs) 66 ± 9 64 ± 15 66 ± 10 ns/ns
LVEF (%) 38 ± 16 33 ± 17 35 ± 14 ns/ns
Post-op hosp. (d) 8±5 5±3 3±2 0.04/001
Charges ($1,0001 24± 9 21 ±4 13 ± 4 ns/O.OO4
The prepectoral implant approach for NTL ICOs led to less postoperative
hospitalization and at least a 35% lower cost as compared to abdominal NTL
or epicardiallCO implant approaches. ICO technology evolution is associated
with lower health care resource utilization per patient. This is an example of
progress in health technology associated with less monetary costs.
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1737-1 I Heart Fatty Acid-binding Protein and Myoglobin can
Accurately Detect Successful Reperfusion as Early
as 15 Minutes After Reperfuslon
Junnichi Ishii, Masanori Nomura, Toshikazu Ando, Mamoru Kimura,
Hiroshi Kurokawa, Takeshi Kondo, Yoshihiko Watanabe, Hitoshi Hishida. Fujita
Health University, Toyoake, Japan
Human heart fatty acid-binding protein (FABP) is an abundant low molecular
weight protein in cytoplasm of myocardial cell similar to myoglobin (Mb). To
evaluate whether FABP can also detect successful reperfusion very early like
Mb, we examined serum FABP and Mb levels in 45 patients (pts) undergoing
PTCR or PTCA within 6 hours after the onset of acute myocardial infarction.
Coronary angiography was performed every 5 minutes (min) during reper-
fusion therapy to determine the exact time of reperfusion. In 30 pts with
reperfusion (reperfused group: TIMI grade 3 [23 pts] and grade 2 [7 pts]),
serum samples were taken just before and at 15, 30 and 60 min after ini-
tial angiographic confirmation of reperfusion. In 15 pts without reperfusion
(nonreperfused group), serum samples were taken just before and at 15, 30
and 60 min after the initiation of therapy. FABP was measured by competi-
tive enzyme immunoassay and Mb by latex agglutination turbidimetry. The
FABP ratio (FABP after/FABP before) and Mb ratio (Mb after/Mb before) were
calculated. FABP and Mb levels increased rapidly, peaked within 60 min after
reperfusion. The FABP and Mb ratios in the reperfused group significantly (p
< 0.01) exceeded those in the nonreperfused group at 15, 30 and 60 min.
The sensitivity (Sen) and specificity (Spe) of these markers for reperfusion
were as follows:
Criteria 15min 30 min 60 min
Sen Spe Sen Spe Sen Spe
FABP ratio> 1.6' 93% 100% 97% 100% 100% 100%
Mb ratio >2.4** 90% 100% 93% 100% 100% 100%
'" mean + 2SD at 60 min in the nonreperfused group, •• published criteria
Conclusion: FABP. like Mb could accurately detect successful reperfusion
as early as 15 min after reperfusion and could provide a high level of accuracy
within 60 min after reperfusion.
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1737-21 Heart Fatty Acid-binding Protein can Provide a
Higher Level of Accuracy than Myoglobin for the
Early Detection of Acute Myocardial Infarction
Junnichi Ishii, Masanori Nomura, Toshikazu Ando, Mamoru Kimura,
Hiroshi Kurokawa, Takeshi Kondo, Yoshihiko Watanabe, Hitoshi Hishida. Fujita
Health University, Toyoake, Japan
Heart fatty acid-binding protein (HFABP) is a cytoplasmic low molecular
weight protein similar to myoglobin 1Mb). The skeletal muscle Mb content
is approximately twice that of the heart while the HFABP concentration in
striated muscle is only 10-50% of that in cardiac muscle. To evaluate the
usefulness of HFABP for the early detection of acute myocardial infarction
(AMI), we measured serum HFABP and Mb levels in the initial samples in
114 patients (pts) brought to our coronary care unit within 3 hours following
onset of symptoms. AMI was confirmed in 63 pts by history, ECG changes
and the pattern of serum CKMB release and was excluded in 51 pts. HFABP
was measured by competitive enzyme immunoassay and Mb by latex ag-
glutination turbidimetry. HFABP in the 63 pts with AMllmean ± SO, 58 ± 50
ng/ml) significantly (p < 0.01) exceeded those in the pts without AMI (8.8 ±
6.2 ng/mll. Figure shows the receiver operating characteristic (ROC) curves
for the detection of AMI within 3 hrs of the onset (1.9 ± 0.7 hrs). The up-
ward and leftward shift in the ROC curve was greater for the HFABP than
the Mb. The sensitivity and specificity of HFABP > 14 ng/ml (mean + 2S0 in
50 healthy volunteers) for the detection of AMI within 3 hours of the onset
were 73% and 80%, respectively. Those of Mb >88 ng/ml(mean + 2S0 in
50 healthy volunteers) were 73% and 61 %, respectively. Conclusion: HFABP
could provide a higher level of accuracy than the Mb for detecting AMI within
3 hours of the onset.
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1737-31 Rapid Whole Blood Bedside Cardiac Troponln T
Immunoassay for the Diagnosis of Acute Myocardial
Infarction
Christian Lovis, Fran,ois Mach, Jean-Claude Chevrolet, Pierre-Fran,ois Unger,
Philip Urban, Jean-Michel Gaspoz. Department of Medicine, Geneva University
Hospital, Switzerland
Cardiac troponin T (cTT) is a regulatory contractile protein normally not found
in the blood. Its detection in the circulation has been shown to be a sensi-
tive and specific marker for acute myocardial infarction (AMI). The Elisa cTT
presently requires at least 90 minutes, which is too long to be useful in emer-
gency situations.
We tested a new rapid bedside whole blood immunoassay for cTT in 32
consecutive patients admitted to the Geneva University Hospital for sus-
pected AMI, with an onset of pain within 12 hours. The new rapid assay,
the Elisa cTT, the creatine kinase (CK) and creatine kinase-MB (CK-MB) were
performed at admission, 4 and 8 hours after admission.
The rapid assay was positive in all 25 patients subsequently shown to have
an AMI. In the 7 patients without AMI, the assay was negative in 6, and posi-
tive in 1 Imyopericarditis). At each time of the three measurements, the rapid
assay had a similar or a better sensitivity and specificity than CK-MB or Elisa
cIT Already 4 hours after admission, the rapid assay reached a sensitivity of
100%, which is better than the CK-MB (96%).
Results of the rapid assay were obtained in 15 minutes, even less in all
positive cases, and the time to get a positive result correlated with the cTT
Elisa and CK-MB levels.
Our results allowed us to conclude that, while considerably more rapid
than conventional assays, this new bedside whole-blood troponin T assay
also has equal or better sensitivity and specificity than the other tests. In
addition, we would like to stress the simplicity of this rapid assay, that can
be performed on the spot, without laboratory infrastructure or equipment.
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1737-41 Serum Cardiac Troponln T Measurements in Unstable
Angina: An Early, Accurate Marker of Increased Risk
Sved A. Abbas, Sol Green, Alan H.B. Wu, Lisa Pearsall, SaJid Dhakam, Rabih Azar,
Mary Onoroski, Ali Senaie, Ravmond G. McKav, David Waters. Hartford Hospital,
University of Connecticut, Hartford, er
Mild myocardial damage due to prolonged ischemia or platelet microemboli
may be common in unstable angina and may be predictive of early com-
plications. To test these hypotheses, we screened 486 consecutive patients
presenting to a hospital emergency room with chest pain to identify 131 with
unstable angina. All had measurements of serum troponin T, creatine kinase
(CK) and CK-MB on admission. A CK level >225 U/l, a CK-MB > 10 nglml or a
troponin T >0.1 Ilg!L were considered elevated. Troponin T levels were not
reported to the treating physician. All patients were followed prospectively
for 3 weeks to tabulate coronary events. Troponin T levels were elevated in 26
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This combined model yielded a C-Index of 0.82, indicating that the strategy
could be clinically useful fordiscriminating between the OPEN from CLOSED
pt groups. This combined strategy is convenient for noninvasively assessing
reperfusion status after TI because it involves a single MYO measurement
and a straightforward clinical indicator.
bolytic therapy (TI) at a median (25th , 75th percentile) of 162 (113, 2261 mins
after onset of symptoms. All pts had acute angiography (Cath) at 142 (96,
195) mins after TI; flow in the IRA was graded as either "OPEN", TIMI 2-3
(n = 71), or "CLOSED", TIMI 0-1 (n = 25). MYO was determined in serial
samples collected before TI (Baseline) and within 10 mins of Cath. MYO val-
ues, in ng/mL, in Baseline samples were similar for the OPEN and CLOSED
groups at 112 (51,275) and 81 (47, 195), respectively; for samples collected
at Cath, values were 915 (501, 2237) for the OPEN group and 273 (159, 855)
for the CLOSED group. MYO strategies based on: 1. MYO Value at Cath, 2.
change from baseline to Cath (Delta), and 3. rate of release (slope) were each
combined with clinical variables for discriminating OPEN from CLOSED pts.
The clinical variables examined were: time from Chest Pain (CP) to TI, time
from TI to Cath, pt weight, pt age, Mllocation, race, and intensity of CP at
Cath graded 0-10. By logistic regression, the best model for discriminating
OPEN from CLOSED pts resulted from combining the following:
patients (20%) and normal in 105. All 8 of the patients with minor elevations
of CK-M B also had elevated troponin T; CK-M B was normal in all patients
with normal troponin T. Patients with elevated troponin T levels were older
(74 ± 10 vs 63 ± 12 years, p < 0.0011 but did not differ from patients with
normal levels with respect to risk factors or other clinical features. However,
as shown in the table, coronary events occurred significantly more frequently
in patients with elevated troponin T levels:
Troponin T on admission: Normal Elevated p
Patients 105 26
Myocardial infarction 3(3%) 8(31%} <0.001
Refractory angina 9(9%) 4(15%} NS
Revascularization 32 (30%) 17 (65'10) ~0.001
Pts with cardiac events 42 (40%) 25 (96'10) <0.001
Only one of the 26 patients with elevated troponin T levels was controlled
with medical therapy alone, compared to 62 of the 105 with normal levels
(4% vs 59%, P < 0.001). The cutpoint of >0.1 j.Lg/L had a sensitivity of 50%
and a specificity of 87% in predicting refractory angina/myocardial infarction.
Conclusion: Serum troponin T levels are elevated on admission in one fifth
of unselected unstable angina patients. These patients have a very high rate
of myocardial infarction and refractory angina despite medical treatment,
and most of them undergo revascularization. Troponin T levels are an inde-
pendent and potentially useful predictor of early coronary events in unstable
angina.
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Stratergy
MYO value at Cath
CP at Cath (o-1O)
Combined Model
1797
7.46
23.95
p-value
0.0002
0.006
>0.000001
[737-51 Risk Stratification in Acute Ischemic Syndromes
Using Serum Tropenin T
E. Magnus Ohman, Paul Armstrong, Robert M. Califf, Mary Ann O'Hanes;an,
Christian W. Hamm, Hugo Katus, Christopher B. Granger, Robert H. Christenson,
Cresha Cianciolo, Eric J. Topol, GUSTO-Ila Investigators. Duke University Medical
Center, Durham, NC
To evaluate whether serum Troponin T (Trop-T) or CK-MB analysis could be
used to risk stratify patients with acute ischemic syndromes, admission
serum samples were obtained in 865 patients enrolled in the GUSTO-lia
study. Pts were stratified on admission into ST elevation (n = 531) and non-
ST elevation (n = 334) groups. CK-MB (mass assay) and Trop-T (immunoas-
say) were measured by an enzymatic core laboratory. The median (25th, 75th
parcentile) serum CK-MB was 2.9 (0.9, 8.2) ng/ml in the non-ST and 4.0 (1.5,
14.1) ng/ml in the ST elevation group. Corresponding Trop-T levels were 0.05
(0.01, 0.27) ng/ml and 0.04 (0.01, 0.33) ng/ml. respectively. Elevated levels
of CK-MB (>7 ng/mll were seen in 33% and Trop-T levels >0.1 ng/ml were
seen in 36% pts. Regression analysis documented that Trop-T levels were
strongly associated with mortality (p < 0.0001 ), while CK-M B levels were less
strongly associated (p = 0.03). In a regression model of both serum markers
and mortality, CK-MB added no information (p = 0.9) after the Trop-T lev-
els were included. Higher admission Trop-T levels were also associated (p
= 0.005) with a poor clinical outcome using a composite endpoint of death,
late (> 18 hours after admission) myocardial infarction/reinfarction (MI), car-
diogenic shock or heart failure (CHF), while only a weak relationship was ob-
served with CK-MB (p = 0.07). Outcomes based on admission Trop-T levels
>0.1 ng/ml (Pos) or <0.1 (Neg) were as shown:
Non-ST Group ST elevation Group
Trop-T Neg Trop-T Pas Trop-T Neg Trop-T Pas
Outcomes N = 201 N ~ 123 N = 324 N = 176
Death 1% 9% 5% 12%
Shock 2% 6% 3% 9%
MI 6% 11% 5% 7%
CHF 7% 16% 10% 15%
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1738-1 1 Five Year Trends in the Treatment of Angiographically
Documented Coronary Artery Disease: Experience of
a Tertiary Care Center
Glenn N. Levine, Jonathan D. Bier, Michael Stucci, Thomas J. Ryan, Alice
K. Jacobs. Boston University Medical Center. Boston, MA
To determine the impact of new technology on the management of pa-
tients with significant (>70% stenosis) coronary artery disease (CAD). we
compared treatment strategies in patients undergoing diagnostic cardiac
catheterization during the years 1987-1989 (group 1) and 1992-1994 (group
21. Patients with significant congenital and valvular disease, left main dis-
ease, and insignificant coronary artery disease were excluded from analysis.
Although there was a higher prevalance of hypertension (60.6% vs 66.6%,
P = 0.024), hypercholesterolemia (32.5% vs 51.5%, P = 0.001), and female
gender (27% vs 33%, P < 0.001), and a lower prevalance of unstable angina
at the time of the procedure (26.8% vs 17.9%. P = 0.001) in group 2, there
were no differences between the two groups in mean age (61 .0 yrs vs 62.5
yrs), incidence of diabetes (26.5% vs 25.2%), tobacco use (58.4% vs 56.1 %1,
peripheral vascular disease (16.3% vs 17.3% ) or cerebrovascular disease
(7.8% vs 6.8%). Although there were more female patients in group 2, the
percent of women and men undergoing revascularization was similar. Treat-
ment strategies were classified as either medical therapy; percutaneous
revascularization; or coronary artery bypass surgery (CABG).
Group 111987-1989J Group 2[1992-19941 p
n (%) n (%) value
Despite technologic advances in percutaneous revascularization, the per-
centage of patients undergoing percutaneous revascularization has not in-
creased. There has been a significant reduction in the percentage of patients
referred for CABG, which may be due to an increasing number of patients
being treated medically. This change in treatment strategy may reflect better
medical therapy and/or increased concern about the risks of revasculariza-
tion.
In conclusion, Troponin T measurements in patients with acute ischemic
syndromes can stratify patients into high and low risk categories. Early and
rapid determination of Troponin T levels has the potential to streamline health
care delivery in patients with acute ischemic syndromes.
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1737-61 Combining Myoglobin and Clinical Variables for
Assessing Coronary Reperfusion After Thrombolytic
Therapy
Robert H. Christenson, E. Magnus Ohman, Kristina N. Sigmon, Mary
Ann O'Hanesian, Gladys L. Alonsozana, Kristin L. Newby, Show-Hong Duh,
Mitchell W. Krucoff, Robert M. Califf, TAMI Study Group. Univ of Maryland,
Baltimore, MD & Duke Univ., Durham, NC
Myoglobin (MYO), measured using a quantitative 10 minute assay, was ex-
amined in combination with clinical variables for assessing infarct related
artery (IRA) patency in 96 MI pts, all of whom received front-loaded throm-
Medical Therapy
Percutaneous Revascularization
CABG
573 (38%)
453 (30%)
490 (32%)
808 (49'10)
472(29%)
370 (22%)
0.001
NS
0.001
